• Guardant Health recently reported second-quarter 2025 earnings showing US$232.09 million in sales, a sharp increase from the previous year, alongside a narrowed net loss and improved basic loss per share; the company also raised its full-year revenue guidance and announced positive clinical study results from its collaboration with the Parker Institute for Cancer Immunotherapy.
• Blood-based monitoring with Guardant Reveal was shown to predict immunotherapy response and disease progression months sooner than standard clinical methods in a large real-world study, highlighting potential advances in cancer care and supporting the company's longer-term growth strategy.
• We'll explore how Guardant Health's upgraded revenue outlook and advances in cancer diagnostics could influence its current investment narrative.

These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Guardant Health Investment Narrative Recap

To be a Guardant Health shareholder, you need confidence in the company's ability to translate innovative liquid biopsy technology and accelerating clinical adoption into sustainable commercial growth, all while managing ongoing losses. The recent upgrade to full-year revenue guidance following strong sales and promising clinical data reinforces the company’s position as a leader in blood-based cancer diagnostics and supports near-term momentum, but it doesn’t fully resolve the concern around persistent cash burn and the lengthy path to profitability.

Among recent announcements, the clinical readout from the RADIOHEAD study stands out: Guardant Reveal's ability to identify immunotherapy response and predict disease progression earlier than existing methods serves as timely validation for one of the company’s most important growth catalysts. Demonstrating real-world utility for Reveal not only strengthens reimbursement and adoption prospects, but also directly supports management’s more optimistic revenue outlook in the quarters ahead.

On the other hand, investors should be aware that high ongoing R&D and SG&A expenses remain a critical issue to watch, particularly if...

Read the full narrative on Guardant Health (it's free!)

Guardant Health's outlook anticipates $1.5 billion in revenue and $80.8 million in earnings by 2028. This scenario relies on a 21.9% annual revenue growth rate and a $494.6 million increase in earnings from the current -$413.8 million.

Uncover how Guardant Health's forecasts yield a $61.27 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Retail investors in the Simply Wall St Community valued Guardant Health between US$61 and US$312, signaling highly varied outlooks from their two analyses. While positive clinical validation is fueling optimism about revenue expansion, concerns around ongoing losses and cash burn weigh on expectations for near-term profitability, so consider the full spectrum of views presented here.

Explore 2 other fair value estimates on Guardant Health - why the stock might be worth over 5x more than the current price!

Build Your Own Guardant Health Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Guardant Health research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Guardant Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Guardant Health's overall financial health at a glance.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• We've found 20 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com